Author: Xiu, Siyu; Dick, Alexej; Ju, Han; Mirzaie, Sako; Abdi, Fatemeh; Cocklin, Simon; Zhan, Peng; Liu, Xinyong
Title: Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities Cord-id: 9jwma2y6 Document date: 2020_6_15
ID: 9jwma2y6
Snippet: [Image: see text] Recently, a novel coronavirus initially designated 2019-nCoV but now termed SARS-CoV-2 has emerged and raised global concerns due to its virulence. SARS-CoV-2 is the etiological agent of “coronavirus disease 2019â€, abbreviated to COVID-19, which despite only being identified at the very end of 2019, has now been classified as a pandemic by the World Health Organization (WHO). At this time, no specific prophylactic or postexposure therapy for COVID-19 are currently available
Document: [Image: see text] Recently, a novel coronavirus initially designated 2019-nCoV but now termed SARS-CoV-2 has emerged and raised global concerns due to its virulence. SARS-CoV-2 is the etiological agent of “coronavirus disease 2019â€, abbreviated to COVID-19, which despite only being identified at the very end of 2019, has now been classified as a pandemic by the World Health Organization (WHO). At this time, no specific prophylactic or postexposure therapy for COVID-19 are currently available. Viral entry is the first step in the SARS-CoV-2 lifecycle and is mediated by the trimeric spike protein. Being the first stage in infection, entry of SARS-CoV-2 into host cells is an extremely attractive therapeutic intervention point. Within this review, we highlight therapeutic intervention strategies for anti-SARS-CoV, MERS-CoV, and other coronaviruses and speculate upon future directions for SARS-CoV-2 entry inhibitor designs.
Search related documents:
Co phrase search for related documents- abl inhibitor and action mechanism: 1
- ace activity and action mechanism: 1
- ace inhibitor and action mechanism: 1, 2, 3, 4
- ace inhibitor and action unknown mechanism: 1
Co phrase search for related documents, hyperlinks ordered by date